Cyclin-Dependent Kinase 4

"Cyclin-Dependent Kinase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.

Descriptor ID	D051358
MeSH Number(s)	D08.811.913.696.620.682.700.646.500.875 D12.644.360.250.451 D12.776.167.200.451 D12.776.476.250.451
Concept/Terms	Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 4 Cyclin Dependent Kinase 4 Cdk4 Cyclin-Dependent Kinase Cdk4 Cyclin Dependent Kinase Cyclin-Dependent Kinase, Cdk4 Cdk4 Protein Cdk4 Protein Kinase Protein Kinase, Cdk4 p34PSK-J3 Kinase p34PSK J3 Kinase Cell Division Protein Kinase 4 PSK-J3 Kinase PSK J3 Kinase Cyclin D-Dependent Kinase CDK4 Cyclin D Dependent Kinase CDK4

Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 4".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
Proline-Directed Protein Kinases [D08.811.913.696.620.682.700.646]
Cyclin-Dependent Kinases [D08.811.913.696.620.682.700.646.500]
Cyclin-Dependent Kinase 4 [D08.811.913.696.620.682.700.646.500.875]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
Cyclin-Dependent Kinases [D12.644.360.250]
Cyclin-Dependent Kinase 4 [D12.644.360.250.451]
Proteins [D12.776]
Cell Cycle Proteins [D12.776.167]
Cyclin-Dependent Kinases [D12.776.167.200]
Cyclin-Dependent Kinase 4 [D12.776.167.200.451]
Intracellular Signaling Peptides and Proteins [D12.776.476]
Cyclin-Dependent Kinases [D12.776.476.250]
Cyclin-Dependent Kinase 4 [D12.776.476.250.451]

Below are MeSH descriptors whose meaning is related to "Cyclin-Dependent Kinase 4".

Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 4".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cyclin-Dependent Kinase 4" by people in this website by year, and whether "Cyclin-Dependent Kinase 4" was a major or minor topic of these publications.

Bar chart showing 21 publications over 14 distinct years, with a maximum of 3 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	2	2
2006	0	1	1
2008	1	0	1
2009	0	1	1
2010	1	1	2
2012	0	1	1
2013	0	2	2
2015	0	1	1
2016	0	1	1
2017	0	2	2
2018	0	1	1
2019	1	1	2
2020	2	1	3
2022	0	1	1

Below are the most recent publications written about "Cyclin-Dependent Kinase 4" by people in Profiles.

Yoshida A, Phillips-Mason P, Tarallo V, Avril S, Koivisto C, Leone G, Diehl JA. Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss. Oncogene. 2022 04; 41(15):2187-2195.

View in: PubMed
Das A, Henderson FC, Alshareef M, Porto GBF, Kanginakudru I, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. MGMT-inhibitor in combination with TGF-ßRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.

View in: PubMed
Das A, Alshareef M, Martinez Santos JL, Porto GBF, McDonald DG, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations. Clin Transl Oncol. 2020 Nov; 22(11):2017-2025.

View in: PubMed
Gao X, Leone GW, Wang H. Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res. 2020; 148:147-169.

View in: PubMed
Yoshida A, Bu Y, Qie S, Wrangle J, Camp ER, Hazard ES, Hardiman G, de Leeuw R, Knudsen KE, Diehl JA. SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 2019 09; 5(9):eaax6352.

View in: PubMed
Qie S, Yoshida A, Parnham S, Oleinik N, Beeson GC, Beeson CC, Ogretmen B, Bass AJ, Wong KK, Rustgi AK, Diehl JA. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.

View in: PubMed
Mills JN, Rutkovsky AC, Giordano A. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018 08; 41:59-65.

View in: PubMed
Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, Gao H, Yang G, Williams JA, Suski JM, Keibler MA, Sicinska E, Gerdemann U, Haining WN, Roberts TM, Polyak K, Gygi SP, Dyson NJ, Sicinski P. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017 06 15; 546(7658):426-430.

View in: PubMed
Giordano SB, Gradishar W. Breast cancer: updates and advances in 2016. Curr Opin Obstet Gynecol. 2017 02; 29(1):12-17.

View in: PubMed
Zhang J, Xu K, Liu P, Geng Y, Wang B, Gan W, Guo J, Wu F, Chin YR, Berrios C, Lien EC, Toker A, DeCaprio JA, Sicinski P, Wei W. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. Mol Cell. 2016 06 16; 62(6):929-942.

View in: PubMed

People

Explore

Similar Concepts

Top Journals